Published in Infect Immun on January 13, 2014
Recent advances in recombinant protein-based malaria vaccines. Vaccine (2015) 0.91
Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnology (2016) 0.88
Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine (2015) 0.85
Plasmodium falciparum gametocyte transit through the cutaneous microvasculature: A new target for malaria transmission blocking vaccines? Hum Vaccin Immunother (2016) 0.80
Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates. Malar J (2016) 0.80
Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles. Pharm Res (2015) 0.80
Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in Mice. Clin Vaccine Immunol (2015) 0.78
Transmission-blocking strategies: the roadmap from laboratory bench to the community. Malar J (2016) 0.77
Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes. Infect Immun (2015) 0.76
Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate. Parasit Vectors (2017) 0.75
Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation. Vaccine (2016) 0.75
Salmonella flagellin acted as an effective fusion partner for expression of Plasmodium falciparum surface protein 25 in Escherichia coli. Hum Vaccin Immunother (2016) 0.75
Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes. Pharm Res (2017) 0.75
Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet (2012) 17.62
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature (1981) 3.88
A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature (1988) 3.31
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One (2008) 2.70
Catalysis of the oxidative folding of ribonuclease A by protein disulfide isomerase: dependence of the rate on the composition of the redox buffer. Biochemistry (1991) 2.19
The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J Immunol (1987) 2.18
Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med (1991) 2.15
Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS One (2008) 2.07
Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect Immun (2008) 1.87
Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun (1994) 1.87
Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Biotechnology (N Y) (1994) 1.87
The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress. EMBO Rep (2006) 1.83
Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A (2006) 1.74
Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci U S A (2008) 1.64
A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One (2009) 1.51
Transmission-blocking vaccines. Chem Immunol (2002) 1.51
Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J Biotechnol (2005) 1.51
Glutathione is required to regulate the formation of native disulfide bonds within proteins entering the secretory pathway. J Biol Chem (2004) 1.47
Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A (2006) 1.39
Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expr Purif (2000) 1.32
Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol (1990) 1.31
Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect Immun (1998) 1.30
Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission. PLoS One (2012) 1.23
Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect Immun (1999) 1.16
Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect Immun (2004) 1.14
N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. Clin Vaccine Immunol (2011) 1.08
The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms. Nat Struct Mol Biol (2005) 1.06
Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Hum Vaccin (2011) 1.06
Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect Immun (2005) 1.05
Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine (2007) 1.03
Transmission blockade of Plasmodium falciparum: its variability with gametocyte numbers and concentration of antibody. Trans R Soc Trop Med Hyg (1987) 1.01
Efficient refolding of aggregation-prone citrate synthase by polyol osmolytes: how well are protein folding and stability aspects coupled? J Biol Chem (2005) 0.99
Alga-produced cholera toxin-Pfs25 fusion proteins as oral vaccines. Appl Environ Microbiol (2013) 0.96
Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum. Trends Parasitol (2011) 0.88
Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons. Vaccine (2013) 0.87
The purification of Plasmodium falciparum macrogametes and/or zygotes prepared from in vitro cultures. Trans R Soc Trop Med Hyg (1983) 0.87
On-column refolding and characterization of soluble human interleukin-15 receptor alpha-chain produced in Escherichia coli. Protein Expr Purif (2003) 0.86
Characterization of epitopes on the 25 kD protein of the macrogametes/zygotes of Plasmodium falciparum. Parasite Immunol (1989) 0.79
Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med (2005) 3.85
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One (2009) 2.49
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 2.18
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One (2008) 1.90
Detection of Plasmodium falciparum in pregnancy by laser desorption mass spectrometry. Am J Trop Med Hyg (2005) 1.81
Surveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serology. PLoS One (2012) 1.81
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine (2005) 1.68
A filter paper method for the detection of Plasmodium falciparum gametocytes by reverse transcription polymerase chain reaction. Am J Trop Med Hyg (2008) 1.54
Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice. Vaccine (2010) 1.54
Short report: modulation of Mycobacterium tuberculosis infection by Plasmodium in the murine model. Am J Trop Med Hyg (2004) 1.54
Enzyme-linked immunosorbent assay for detection of Plasmodium falciparum histidine-rich protein 2 in blood, plasma, and serum. Clin Vaccine Immunol (2008) 1.52
A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One (2009) 1.51
Genome annotation of Anopheles gambiae using mass spectrometry-derived data. BMC Genomics (2005) 1.51
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One (2013) 1.47
Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One (2008) 1.47
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials (2006) 1.47
Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One (2008) 1.46
Malaria parasite invasion of the mosquito salivary gland requires interaction between the Plasmodium TRAP and the Anopheles saglin proteins. PLoS Pathog (2009) 1.44
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials (2006) 1.36
Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg (2006) 1.30
Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis (2011) 1.28
Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine (2004) 1.24
Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS One (2010) 1.24
Knowledge attitudes and practices of grade three primary schoolchildren in relation to schistosomiasis, soil transmitted helminthiasis and malaria in Zimbabwe. BMC Infect Dis (2011) 1.21
Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun (2002) 1.20
Aquaporin 9 is the major pathway for glycerol uptake by mouse erythrocytes, with implications for malarial virulence. Proc Natl Acad Sci U S A (2007) 1.18
Involvement of gonadal steroids and gamma interferon in sex differences in response to blood-stage malaria infection. Infect Immun (2006) 1.15
A proteogenomic analysis of Anopheles gambiae using high-resolution Fourier transform mass spectrometry. Genome Res (2011) 1.14
Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect Immun (2004) 1.14
Aquaglyceroporin PbAQP during intraerythrocytic development of the malaria parasite Plasmodium berghei. Proc Natl Acad Sci U S A (2007) 1.13
Purified malaria pigment (hemozoin) enhances dendritic cell maturation and modulates the isotype of antibodies induced by a DNA vaccine. Infect Immun (2002) 1.13
Infection with parasitic nematodes confounds vaccination efficacy. Vet Parasitol (2007) 1.10
Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect Immun (2005) 1.10
Marked variation in MSP-119 antibody responses to malaria in western Kenyan highlands. BMC Infect Dis (2012) 1.07
Transdermal Diagnosis of Malaria Using Vapor Nanobubbles. Emerg Infect Dis (2015) 1.06
A proteomic analysis of salivary glands of female Anopheles gambiae mosquito. Proteomics (2005) 1.05
Plasmodium falciparum enolase: stage-specific expression and sub-cellular localization. Malar J (2009) 1.04
Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine (2007) 1.03
Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Vaccine (2011) 1.03
Impact of schistosome infection on Plasmodium falciparum Malariometric indices and immune correlates in school age children in Burma Valley, Zimbabwe. PLoS Negl Trop Dis (2010) 1.02
Structure of a gametocyte protein essential for sexual development in Plasmodium falciparum. Nat Struct Biol (2003) 1.01
Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. Infect Immun (2008) 1.01
Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin Vaccine Immunol (2012) 1.00
Miniaturization of a high-throughput pLDH-based Plasmodium falciparum growth inhibition assay for small volume samples from preclinical and clinical vaccine trials. Am J Trop Med Hyg (2008) 0.99
Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum. J Biol Chem (2003) 0.99
Rapid detection of malaria infection in vivo by laser desorption mass spectrometry. Am J Trop Med Hyg (2004) 0.98
C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int Immunol (2005) 0.98
Molecular players of homologous recombination in protozoan parasites: implications for generating antigenic variation. Infect Genet Evol (2004) 0.97
Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo. Chem Biol (2009) 0.97
Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. Vaccine (2010) 0.97
Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. Clin Vaccine Immunol (2007) 0.96
Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42). Am J Trop Med Hyg (2005) 0.95
Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2009) 0.93
Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect Immun (2013) 0.93
Identification and molecular characterisation of DNA damaging agent induced expression of Plasmodium falciparum recombination protein PfRad51. Int J Parasitol (2003) 0.92
MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum. Malar J (2009) 0.92
Exacerbation of Plasmodium yoelii malaria in Echinostoma caproni infected mice and abatement through anthelmintic treatment. J Parasitol (2005) 0.92
Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect Immun (2004) 0.92
Centrins, cell cycle regulation proteins in human malaria parasite Plasmodium falciparum. J Biol Chem (2008) 0.92
Critical role of a K+ channel in Plasmodium berghei transmission revealed by targeted gene disruption. Proc Natl Acad Sci U S A (2008) 0.92
Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy. Malar J (2010) 0.92
Anti-sporozoite antibodies as alternative markers for malaria transmission intensity estimation. Malar J (2014) 0.92
Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen. PLoS One (2013) 0.91
Mycobacterium-induced potentiation of type 1 immune responses and protection against malaria are host specific. Infect Immun (2005) 0.90
Antibody responses to Plasmodium falciparum vaccine candidate antigens in three areas distinct with respect to altitude. Acta Trop (2006) 0.90
Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies. Malar J (2008) 0.90
Plasmodium yoelii: adverse outcome of non-lethal P. yoelii malaria during co-infection with Schistosoma mansoni in BALB/c mouse model. Exp Parasitol (2009) 0.89
Cytokine and antibody responses to Plasmodium falciparum in naïve individuals during a first malaria episode: effect of age and malaria exposure. PLoS One (2013) 0.88
Extra terminal residues have a profound effect on the folding and solubility of a Plasmodium falciparum sexual stage-specific protein over-expressed in Escherichia coli. Eur J Biochem (2002) 0.88
Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons. Vaccine (2013) 0.87
Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice. Biotechnol J (2011) 0.86
A modified Plasmodium falciparum growth inhibition assay (GIA) to assess activity of plasma from malaria endemic areas. Exp Parasitol (2006) 0.85
High prevalence of molecular markers for resistance to chloroquine and pyrimethamine in Plasmodium falciparum from Zimbabwe. Parasitol Res (2007) 0.85
Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens. PLoS One (2011) 0.85
High antibody responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria. PLoS One (2013) 0.84
Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol (2005) 0.84
Molecular vaccines for malaria. Hum Vaccin (2010) 0.84
Functional analysis of Plasmodium falciparum parasitophorous vacuole membrane protein (Pfs16) during gametocytogenesis and gametogenesis by targeted gene disruption. Mol Biochem Parasitol (2004) 0.84
Enhanced malaria parasite transmission from helminth co-infected mice. Am J Trop Med Hyg (2007) 0.84
Host microsatellite alleles in malaria predisposition? Malar J (2005) 0.83
Opposing roles for two molecular forms of replication protein A in Rad51-Rad54-mediated DNA recombination in Plasmodium falciparum. MBio (2013) 0.83
C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine (2007) 0.83
Plasmodium falciparum protein phosphatase type 1 functionally complements a glc7 mutant in Saccharomyces cerevisiae. Int J Parasitol (2002) 0.83
Counter-regulatory anti-parasite cytokine responses during concurrent Plasmodium yoelii and intestinal helminth infections in mice. Exp Parasitol (2008) 0.83
Characterization of kinetics of DNA strand-exchange and ATP hydrolysis activities of recombinant PfRad51, a Plasmodium falciparum recombinase. Mol Biochem Parasitol (2005) 0.83
Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis. Vaccine (2009) 0.82
A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies. Infect Immun (2013) 0.82
Antimalarial Preclinical Drug Development: A Single Oral Dose of A 5-Carbon-linked Trioxane Dimer Plus Mefloquine Cures Malaria-Infected Mice. Drug Dev Res (2009) 0.82
Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines. Eukaryot Cell (2008) 0.81
Functional characterisation of sexual stage specific proteins in Plasmodium falciparum. Int J Parasitol (2002) 0.81
Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine. Malar J (2012) 0.81
Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8. Infect Immun (2012) 0.81
A compendium of molecules involved in vector-pathogen interactions pertaining to malaria. Malar J (2013) 0.81
A chemiluminescent-western blot assay for quantitative detection of Plasmodium falciparum circumsporozoite protein. J Immunol Methods (2013) 0.80